C51H56N16O4
Neat
957.12
Linagliptin Methyl Dimer; 2463617-49-2; Linagliptin Impurity; 8-(3-Aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-1-((4-(2-((1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2, 6-dioxo-2, 3, 6, 7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)amino)ethyl)quinazolin-2-yl)methyl)-3-methyl-1H-purine-2, 6(3H, 7H)-dione;; Linagliptin Impurity 136; 8-((R)-3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-1-((4-(2-(((R)-1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2, 6-dioxo-2, 3, 6, 7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)amino)ethyl)quinazolin-2-yl)methyl)-3-methyl-3, 7-dihydro-1H-purine-2 and 6-dione
8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-1-[[4-[2-[[(3R)-1-[7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-2, 6-dioxopurin-8-yl]piperidin-3-yl]amino]ethyl]quinazolin-2-yl]methyl]-3-methylpurine-2 and 6-dione
InChI=1S/C51H56N16O4/c1-6-8-26-64-42-44(58-48(64)62-24-14-16-33(52)28-62)60(4)51(71)67(47(42)69)31-41-56-38-21-13-11-19-36(38)39(57-41)22-23-53-34-17-15-25-63(29-34)49-59-45-43(65(49)27-9-7-2)46(68)66(50(70)61(45)5)30-40-54-32(3)35-18-10-12-20-37(35)55-40/h10-13,18-21,33-34,53H,14-17,22-31,52H2,1-5H3/t33-,34-/m1/s1